ArticleJournal of liposome research2007
"Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes.
Article in Journal of liposome research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 128 citations in OpenAlex.
- Can breakthroughs in dermal and transdermal macromolecule delivery surmount existing barriers and revolutionize future therapeutics?Journal of translational medicine · 2025Review
- The Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System.International journal of molecular sciences · 2025Review
- Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.International journal of molecular sciences · 2023Review
- Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications.Vaccines · 2023Review
- Controlled and Targeted Drug Delivery Using Smart Nanovectors.International journal of drug discovery and pharmacology · 2023Article
- A cationic lipid mediated CRISPR/Cas9 technique for the production of stable genome edited citrus plants.Plant methods · 2022Article
- Recent advances in peptide-based nanomaterials for targeting hypoxia.Nanoscale advances · 2021Review
- Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity.Scientific reports · 2021Article
- Physical Properties of Nanoparticles That Result in Improved Cancer Targeting.Journal of oncology · 2020Review
- Real-time tracking of single-molecule collagenase on native collagen and partially structured collagen-mimic substrates.Chemical communications (Cambridge, England) · 2018Article
- Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.Nanotechnology reviews · 2018Article
- Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery.Drug delivery · 2017Review
- Interrogating Cellular Functions with Designer Janus Particles.Chemistry of materials : a publication of the American Chemical Society · 2017Article
- Effect of partial PEGylation on particle uptake by macrophages.Nanoscale · 2017Article
- In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.Drug design, development and therapy · 2017Article
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacological reviews · 2016Review
- Anchoring dipalmitoyl phosphoethanolamine to nanoparticles boosts cellular uptake and fluorine-19 magnetic resonance signal.Scientific reports · 2015Article
- Modifications of natural peptides for nanoparticle and drug design.Advances in protein chemistry and structural biology · 2015Review
- Investigation of Fatty Acid Ketohydrazone Modified Liposome's Properties as a Drug Carrier.Journal of drug delivery · 2015Article
- An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.International journal of nanomedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
To engineer drug carriers capable of spontaneous accumulation in tumors and ischemic areas via the enhanced permeability and retention (EPR) effect and further penetration and drug delivery inside tumor or ischemic cells via the action of the cell-penetrating peptide (CPP), we have prepared liposomes simultaneously bearing on their surface CPP (TAT peptide, TATp) moieties and protective PEG chains. PEG chains were incorporated into the liposome membrane via the PEG-attached phosphatidylethanolamine (PE) residue with PEG and PE being conjugated with the lowered pH-degradable hydrazone bond (PEG-HZ-PE). Under normal conditions, liposome-grafted PEG "shielded" liposome-attached TATp moieties since the PEG spacer for TATp attachment (PEG(1000)) was shorter than protective PEG(2000). PEGylated liposomes are expected to accumulate in targets via the EPR effect, but inside the "acidified" tumor or ischemic tissues lose their PEG coating due to the lowered pH-induced hydrolysis of HZ and penetrate inside cells via the now-exposed TATp moieties. This concept is shown here to work in cell cultures in vitro as well as in ischemic cardiac tissues in the Langendorff perfused rat heart model and in tumors in experimental mice in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.